Onesource Specialty Pharma Limited has informed the Exchange regarding in-principle approval provided by the Board of Directors to evaluate acquisition of Sterile Injectable CDMO and CMO businesses of Steriscience Pte. Limited ( SteriScience SG ) and Brooks Steriscience Limited.'.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts less than Nifty Smallcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Onesource Specialty Pharma's Board has given in-principle approval to explore acquiring the Sterile Injectable CDMO and CMO businesses of Steriscience Pte. Limited and Brooks Steriscience Limited. The deal would add a USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, and an integrated USFDA-approved carbapenem facility in Vadodara, India. Both target entities are majority-owned directly or indirectly by the company's Promoters, making this a related-party transaction. The Board has only authorized management to begin evaluation, appoint advisors, valuers, and merchant bankers, and recommend an optimal structure. The transaction is not finalized, and further disclosures will follow once the Board formally considers and approves the matter.
Strategically positive as it would expand Onesource's global CDMO footprint with two USFDA-approved facilities, but shareholders should watch the valuation closely since the sellers are promoter-related entities. The stock may see short-term volatility; final deal terms and pricing will be the key triggers.